About Regeneron
Industry:
Biotechnology
Founded:
1988
Founders:
Leonard Schleifer, George Yancopoulos
Status:
Public (NASDAQ: REGN)
Funding & Growth
Total Raised:
N/A
Valuation:
$90B+ market cap
Stage:
Public
Key Investors:
Public markets
✓ Pros
- • Strong drug pipeline
- • Excellent genetics research
- • Founder-led company
- • Good compensation
- • Stable financials
✗ Cons
- • Tarrytown, NY location
- • Less startup-like culture
- • Some siloed teams
- • Traditional pharma aspects